Chemomab

Chemomab is a clinical-stage biotechnology company focused on discovering and developing innovative therapies for diseases with unmet needs, such as inflammation and fibrosis. Chemomab has made significant progress with its novel proprietary CM-101 platform, which impedes the essential function of soluble chemokine CCL24 as a key modulator of inflammatory and fibrotic pathways in various fibrosis-related conditions.The company’s lead clinical candidate, CM-101, is a first-in-class monoclonal antibody targeting CCL24. Chemomab studies have shown that CM-101 interferes with the fundamental biology of fibrosis through a novel mechanism of action.Chemomab is actively advancing CM-101 into Phase 2 studies for the treatment of patients with liver fibrosis (primary sclerosing cholangitis and non-alcoholic steatohepatitis) as well as patients with skin and lung fibrosis (systemic sclerosis).